Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Virios Therapeutics Inc VIRI

Healthcare Biotechnology
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VIRI)

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

GlobeNewswire March 26, 2024

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 29, 2024

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

GlobeNewswire February 28, 2024

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

GlobeNewswire January 22, 2024

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

GlobeNewswire January 2, 2024

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

GlobeNewswire November 6, 2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

GlobeNewswire October 12, 2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

GlobeNewswire September 18, 2023
View More News ››

Opinion & Analysis (NDAQ:VIRI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VIRI)

VIRI ..... LoL

imploding? sub $1.00 now.....they're still making bank on the 50 cent financing last Sept
Iseneschal - April 25, 2023

VIRI....another 15 minute wonder

reached the H.O.D $1.43 then the big waterfall to the L.O.D  $1.04....now sideways action on declining volume Go chit in a river...
Iseneschal - April 25, 2023

VIRI.....Changing hats

from Herpes to Fibromyalgia 50 cent financing way back when On watch
Iseneschal - April 25, 2023

VIRI..... On watch list

Cheaper than a Large Slurpee ; )  Cheers
Iseneschal - September 22, 2022
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp is a Canadian company engaged in the acquisition, exploration, and development of natural ...
View More »